Table 7 Characteristics of the patient population

Age

283 (100 %)

134 (100 %)

149 (100 %)

≤50 years

57 (20 %)

20 (15 %)

37 (25 %)

51–60 years

67 (24 %)

26 (19 %)

41 (28 %)

>60 years

159 (56 %)

88 (66 %)

71 (48 %)

Median age (years)

62

67

60

Age range (years)

23–87

39–87

23–87

Follow-up

Death

99 (35 %)

61 (46 %)

38 (26 %)

Alive

184 (65 %)

73 (54 %)

111 (74 %)

Mean follow-up (days)

162

141

180

Median follow-up (days)

59

56

83

Range (days)

0–832

0–832

0–774

Gender

Female

121 (43 %)

62 (46 %)

59 (40 %)

Male

162 (57 %)

72 (54 %)

90 (60 %)

Non-malignant disease

Hepatic failure

180 (63 %)

49 (36 %)

131 (88 %)

Gastrointestinal disease

104 (37 %)

36 (27 %)

68 (46 %)

Cardiac disease

80 (28 %)

33 (24 %)

47 (32 %)

Renal failure

47 (17 %)

22 (16.%)

25 (17 %)

Hepatitis A, B, C, D, or E, or autoimmune disease

46 (16 %)

18 (13 %)

28 (19 %)

Hepatorenal syndrome

40 (14 %)

11 (8 %)

29 (19 %)

Portal hypertension

25 (9 %)

4 (3 %)

21 (14 %)

Lung diseases

24 (8 %)

13 (9 %)

11 (7 %)

Sepsis

23 (8 %)

7 (5 %)

16 (11 %)

Hepatic encephalopathy

20 (7 %)

5 (4 %)

15 (10 %)

Pneumonia

16 (6 %)

5 (4 %)

11 (7 %)

Portal vein thrombosis

15 (5 %)

7 (5 %)

8 (5 %)

Pancreatitis

14 (5 %)

2 (1 %)

12 (8 %)

Peritonitis

14 (5 %)

2 (1 %)

12 (8 %)

Hemic disease

12 (4 %)

3 (2 %)

9 (6 %)

Others (benign tumors, urologic diseases, etc.)

10 (4 %)

4 (3 %)

6 (4 %)

Cytology result

Positive

35 (12 %)

35 (26 %)

0 (0 %)

Negative

226 (80 %)

80 (60 %)

146 (98 %)

Suspicious

22 (8 %)

19 (14 %)

3 (2 %)